Urology Clinics of North Texas
Welcome,         Profile    Billing    Logout  
 37 Trials 
92 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sanchez, Maria Carmen
GRAFD, NCT04502823: Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler

Completed
N/A
1088
Europe
Management based on sFlt-1/PlGF values
Hospital Universitari Vall d'Hebron Research Institute
Fetal Growth Retardation
12/22
12/22
NCT06551779: Efficacy of Perineural Injection With Dextrose Versus Therapy Conventional Physics in Patients With Bell's Palsy

Completed
N/A
21
RoW
inyección perineural con solución de dextrosa tamponada
Celia Itxelt Infante Castro, ARIANA GUADALUPE MARTINEZ SILVA, MARIA DE LOS ANGELES HERNANDEZ SANCHEZ, MERCEDES DE JESUS JUAREZ LOPEZ, IVAN HUERTA GRANADA, MARIA CATALINA SANTIAGO SANTIAGO, VICTOR MANUEL CAMARILLO NAVA
Bell´s Palsy
05/24
05/24
VALRESCIC, NCT05491291: Chronic Wound Care of Lower Limb in M@diCICAT Center at CHU de Martinique

Not yet recruiting
N/A
120
RoW
Patients with chronic wound of the lower limbs
University Hospital Center of Martinique
Chronic Wounds
05/24
08/24
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
N/A
586
Europe, Japan, US, RoW
isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib
Sanofi
Plasma Cell Myeloma
02/26
02/26
Chevli, Kent
STREAM, NCT05383274: Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Recruiting
4
34
US
Optilume Urethral DCB
Urotronic Inc., Laborie Medical Technologies Inc.
Urethral Stricture
12/25
12/26
UTOPIA, NCT06331299: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Recruiting
3
92
US
UGN-103, UGN-103 (mitomycin) for intravesical solution
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
08/25
08/26
Nordquist, Luke
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting
4
700
Europe, Canada, US, RoW
AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Novartis Pharmaceuticals
Prostate Cancer
07/33
07/33
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
CURLu177PSM0001, NCT05204927: 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
439
Europe, US
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Curium US LLC
Metastasis From Malignant Tumor of Prostate
08/24
02/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hourglass May 2024 - Dec 2024 : Completion of enrollment in P2 portion for mCRPC
Recruiting
2/3
100
US
FPI-2265
Fusion Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
07/26
01/31
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
TATCIST, NCT05219500: Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer ().

Active, not recruiting
2
115
US
FPI-2265, Ac225-PSMA I&T
Fusion Pharmaceuticals Inc.
Metastatic Castration Resistant Prostate Cancer
04/25
07/25
CONVERGE-01, NCT06549465: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Recruiting
2
47
US
In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 55 kBq/kg Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan
Convergent Therapeutics
PSMA PET-Positive Castration-Resistant Prostate Cancer
12/25
04/27
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting
2
234
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
10/27
03/28
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Recruiting
2
219
US
Enoblituzumab, MGA271, Standard of Care
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
03/29
03/29
NCT05286840: 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Not yet recruiting
1/2
150
US
64Cu-SAR-bisPSMA
Luke Nordquist, MD, Clarity Pharmaceuticals
Prostate Cancer
03/23
09/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
COMBAT, NCT05633160: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617

Recruiting
1/2
38
US
64Cu-SAR-BBN, 67Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
05/26
05/26
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
141
US
ONC-392 low, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan, Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
SECuRE, NCT04868604: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Recruiting
1/2
44
US
64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
09/26
09/26
ONCT-534-101, NCT05917470: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Terminated
1/2
21
Europe, US
ONCT-534, GTx-534, UT-34
Oncternal Therapeutics, Inc
Metastatic Castration-resistant Prostate Cancer
09/24
09/24
NCT05773703: Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Completed
1
23
US
PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122
Ratio Therapeutics, Inc.
Prostate Cancer
12/23
12/23
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Recruiting
1
30
US
²¹²Pb-DOTAM-GRPR1
Orano Med LLC
Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
08/24
01/25
NCT05605522: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Active, not recruiting
1
42
US, RoW
[225]-FPI-2059, [111In]-FPI-2058
Fusion Pharmaceuticals Inc.
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
06/25
09/25
Kernen, Kenneth
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Trainer, Andrew
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
10/24
03/29
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Recruiting
N/A
500
US
Data collection
Urotronic Inc.
Benign Prostatic Hyperplasia
03/27
03/27
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
Cochran, James
BlueHaloCoil, NCT05714488: Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction

Recruiting
N/A
95
US
blue halo coil catheter
Blue Halo Biomedical, LLC
Urinary Retention
09/24
10/24
Shore, Neal D
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study

Recruiting
3
100
Europe, US, RoW
padeliporfin VTP, WST11
Steba Biotech S.A., PrimeVigilance, ICON plc
Transitional Cell Cancer of Renal Pelvis and Ureter
06/25
01/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
NCT06636682: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Recruiting
2
100
US
FK-PC101, Standard of Care (SOC)
Cellvax Therapeutics Inc
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
02/27
05/27
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1
24
US
ZH9
Prokarium Ltd
NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
06/25
07/27
FORAGER-1, NCT05614739: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
535
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, enfortumab vedotin
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/27
06/27
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

Completed
N/A
804
Europe, Canada, US
Micro-US Targeted Biopsy, MRI Targeted Biopsy
Sunnybrook Health Sciences Centre, Exact Imaging
Prostate Cancer
09/24
11/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

Active, not recruiting
N/A
554
Canada, US
Cxbladder
Pacific Edge Limited
Hematuria, Urothelial Carcinoma
12/24
12/24
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Tewari, Ashutosh K
NCT06945315: SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

Recruiting
3
196
US
RALP (Robotic-assisted radical prostatectomy), SAFE (Saline assisted fascial engorgement)
Icahn School of Medicine at Mount Sinai
Prostate Cancer, Erectile Dysfunction
07/27
07/27
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
NCT06343077: Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Recruiting
2
114
US
Poly-ICLC intramuscular (IM) injection, Hiltonol®, Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, Poly-ICLC, Intertumoral (IT) injection
Ashutosh Kumar Tewari, Oncovir, Inc.
Prostate Cancer Patients on Active Surveillance
12/26
12/26
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
NCT06906471: A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Not yet recruiting
1/2
10
US
AS1986NS
Antelope Surgical Solutions, Inc
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
12/25
03/26
PGV-Prostate, NCT05010200: The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Active, not recruiting
1
27
US
PGV-001, Poly-ICLC, CDX-301
Ashutosh Kumar Tewari
Prostate Cancer
01/27
01/28
NCT04761107: Impact of COVID-19 on GU Disease

Active, not recruiting
N/A
15240
US
Icahn School of Medicine at Mount Sinai
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
02/26
02/26
Osterhout, Danielle
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT06533644: A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
70
US
Partial Oncolysis, cryolysis, SV-102
Syncromune, Inc.
Metastatic Castration-resistant Prostate Cancer
12/27
12/27
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Wilner, Matthew
ORIC-944-01, NCT05413421: Study of ORIC-944 in Patients with Metastatic Prostate Cancer

Recruiting
1
250
Europe, US, RoW
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
ORIC Pharmaceuticals
Metastatic Prostate Cancer
12/25
09/26
Barnette
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Active, not recruiting
2
150
US
Enobosarm, Semaglutide, Wegovy
Veru Inc.
Muscle Loss, Obesity
12/24
04/25
NCT03752099: To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Terminated
1b/2
80
US
VERU-111, Bisindole
Veru Inc.
Metastatic Castration Resistant Prostate Cancer
03/23
03/23
Thoreson, Gregory
SEPTA, NCT04583072: Stockholm3 Validation Study in a Multi-Ethnic Cohort

Completed
N/A
2152
Canada, US
The Stockholm3 test, Diagnostic Test: Custom ancestry informative genetic markers
Karolinska Institutet, University of Illinois at Chicago, UroPartners, University of Chicago, Rush University Medical Center, Montefiore Medical Center, The University of Texas Health Science Center at San Antonio, Cook County Health & Hospitals System, Cook County Health, Stanford University, Northwestern Medicine, University of Southern California, University Health Network, Toronto, Urology Clinics of North Texas, LAC+USC Medical Center
Prostate Cancer (Diagnosis)
07/23
07/23
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Grewal, Shaun GS
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
Mehllhaff, Bryan
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
Park, Gerald
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
Valverde, Christian
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sanchez, Maria Carmen
GRAFD, NCT04502823: Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler

Completed
N/A
1088
Europe
Management based on sFlt-1/PlGF values
Hospital Universitari Vall d'Hebron Research Institute
Fetal Growth Retardation
12/22
12/22
NCT06551779: Efficacy of Perineural Injection With Dextrose Versus Therapy Conventional Physics in Patients With Bell's Palsy

Completed
N/A
21
RoW
inyección perineural con solución de dextrosa tamponada
Celia Itxelt Infante Castro, ARIANA GUADALUPE MARTINEZ SILVA, MARIA DE LOS ANGELES HERNANDEZ SANCHEZ, MERCEDES DE JESUS JUAREZ LOPEZ, IVAN HUERTA GRANADA, MARIA CATALINA SANTIAGO SANTIAGO, VICTOR MANUEL CAMARILLO NAVA
Bell´s Palsy
05/24
05/24
VALRESCIC, NCT05491291: Chronic Wound Care of Lower Limb in M@diCICAT Center at CHU de Martinique

Not yet recruiting
N/A
120
RoW
Patients with chronic wound of the lower limbs
University Hospital Center of Martinique
Chronic Wounds
05/24
08/24
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
N/A
586
Europe, Japan, US, RoW
isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib
Sanofi
Plasma Cell Myeloma
02/26
02/26
Chevli, Kent
STREAM, NCT05383274: Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Recruiting
4
34
US
Optilume Urethral DCB
Urotronic Inc., Laborie Medical Technologies Inc.
Urethral Stricture
12/25
12/26
UTOPIA, NCT06331299: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Recruiting
3
92
US
UGN-103, UGN-103 (mitomycin) for intravesical solution
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
08/25
08/26
Nordquist, Luke
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting
4
700
Europe, Canada, US, RoW
AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Novartis Pharmaceuticals
Prostate Cancer
07/33
07/33
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
CURLu177PSM0001, NCT05204927: 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
439
Europe, US
177Lu-PSMA-I&T, Abiraterone with Prednisone or Enzalutamide
Curium US LLC
Metastasis From Malignant Tumor of Prostate
08/24
02/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
DASL-HiCaP, NCT04136353: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting
3
1100
Europe, Canada, US, RoW
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/28
07/28
AlphaBreak, NCT06402331: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hourglass May 2024 - Dec 2024 : Completion of enrollment in P2 portion for mCRPC
Recruiting
2/3
100
US
FPI-2265
Fusion Pharmaceuticals Inc.
Metastatic Castration-resistant Prostate Cancer
07/26
01/31
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Completed
2
61
US
GT0918, proxalutamide, androgen receptor antagonist
Suzhou Kintor Pharmaceutical Inc,
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
03/22
09/22
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
TATCIST, NCT05219500: Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer ().

Active, not recruiting
2
115
US
FPI-2265, Ac225-PSMA I&T
Fusion Pharmaceuticals Inc.
Metastatic Castration Resistant Prostate Cancer
04/25
07/25
CONVERGE-01, NCT06549465: Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

Recruiting
2
47
US
In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 55 kBq/kg Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan
Convergent Therapeutics
PSMA PET-Positive Castration-Resistant Prostate Cancer
12/25
04/27
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting
2
234
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
10/27
03/28
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
HEAT, NCT06014255: Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer

Recruiting
2
219
US
Enoblituzumab, MGA271, Standard of Care
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics
Prostate Cancer
03/29
03/29
NCT05286840: 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

Not yet recruiting
1/2
150
US
64Cu-SAR-bisPSMA
Luke Nordquist, MD, Clarity Pharmaceuticals
Prostate Cancer
03/23
09/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
COMBAT, NCT05633160: 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617

Recruiting
1/2
38
US
64Cu-SAR-BBN, 67Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
05/26
05/26
PRESERVE-006, NCT05682443: ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Recruiting
1/2
141
US
ONC-392 low, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan, Pluvicto
OncoC4, Inc., Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer
06/26
06/27
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
SECuRE, NCT04868604: 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer

Recruiting
1/2
44
US
64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostatic Neoplasms, Castration-Resistant
09/26
09/26
ONCT-534-101, NCT05917470: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

Terminated
1/2
21
Europe, US
ONCT-534, GTx-534, UT-34
Oncternal Therapeutics, Inc
Metastatic Castration-resistant Prostate Cancer
09/24
09/24
NCT05773703: Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Completed
1
23
US
PSMA-Targeted [In-111]-Labeled Trillium Compound, PTI-122
Ratio Therapeutics, Inc.
Prostate Cancer
12/23
12/23
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05283330: Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Recruiting
1
30
US
²¹²Pb-DOTAM-GRPR1
Orano Med LLC
Cervical Cancer, Prostate Cancer Metastatic, Breast Cancer, Colon Cancer, NSCLC, Cutaneous Melanoma
08/24
01/25
NCT05605522: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Active, not recruiting
1
42
US, RoW
[225]-FPI-2059, [111In]-FPI-2058
Fusion Pharmaceuticals Inc.
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer
06/25
09/25
Kernen, Kenneth
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Trainer, Andrew
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
10/24
03/29
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
APEX, NCT06560476: OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH

Recruiting
N/A
500
US
Data collection
Urotronic Inc.
Benign Prostatic Hyperplasia
03/27
03/27
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
Cochran, James
BlueHaloCoil, NCT05714488: Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction

Recruiting
N/A
95
US
blue halo coil catheter
Blue Halo Biomedical, LLC
Urinary Retention
09/24
10/24
Shore, Neal D
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
ENLIGHTED, NCT04620239 / 2020-004494-41: ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer () Study

Recruiting
3
100
Europe, US, RoW
padeliporfin VTP, WST11
Steba Biotech S.A., PrimeVigilance, ICON plc
Transitional Cell Cancer of Renal Pelvis and Ureter
06/25
01/29
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1144
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
3
496
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
PSMA-DC, NCT05939414: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Recruiting
3
450
Europe, Canada, Japan, US, RoW
AAA617, (177Lu) vipivotide tetraxetan
Novartis Pharmaceuticals
Oligometastatic Prostate Cancer (OMPC)
12/27
07/30
SABRE, NCT05407311: 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer

Completed
2
53
US
64Cu-SAR-BBN
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
05/24
05/24
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
CORE-008, NCT06567743: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
200
US
Cretostimogene Grenadenorepvec, CG0070
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
NCT06636682: FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Recruiting
2
100
US
FK-PC101, Standard of Care (SOC)
Cellvax Therapeutics Inc
Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
02/27
05/27
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
Tamarack, NCT05551117: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Hourglass Sep 2024 - Sep 2024 : Updated safety and efficacy data for mCRPC
Completed
2
192
Europe, US, RoW
vobramitamab duocarmazine 2.0 mg (Arm A), MGC018, vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine, Abiraterone, Enzalutamide
MacroGenics
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Anal Cancer, Anal Neoplasm, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Malignant Melanoma, Melanoma, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Small-cell Lung Cancer, Small Cell Carcinoma
07/24
01/25
PSMACare, NCT05849298: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Recruiting
2
120
Europe, Canada, US, RoW
AAA617, Lutetium [177Lu] vipivotide tetraxetan, 177Lu-PSMA-617, AAA517, 68Ga-PSMA-11, Piflufolastat F 18, ARPI, ADT, Best supportive care
Novartis Pharmaceuticals
Prostatic Neoplasm
10/27
12/28
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
COBRA, NCT05249127: 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer

Completed
1/2
52
US
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Biochemical Recurrence of Malignant Neoplasm of Prostate
08/23
08/23
LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting
1/2
350
Europe, Canada, US, RoW
EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2
enGene, Inc.
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
06/26
11/28
NCT05617040: Prime-boost Immunotherapeutic Trial in Men with Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Terminated
1/2
22
US
ChAdOx1-PCAQ, MVA-PCAQ
Barinthus Biotherapeutics
Prostate Cancer
02/25
02/25
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
PARADIGM-1, NCT06181266: A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1
24
US
ZH9
Prokarium Ltd
NMIBC, High Risk NMIBC, Non Muscle Invasive Bladder Cancer
06/25
07/27
FORAGER-1, NCT05614739: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Recruiting
1
535
Europe, Canada, Japan, US, RoW
LOXO-435, LY3866288, Pembrolizumab, enfortumab vedotin
Eli Lilly and Company, Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
06/27
06/27
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
BREEZE, NCT04987138: Safety and Effectiveness Study of the Zenflow Spring System

Active, not recruiting
N/A
279
US
Zenflow Spring System, Sham Procedure, Foley Catheter
Zenflow, Inc.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
06/24
06/26
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

Completed
N/A
804
Europe, Canada, US
Micro-US Targeted Biopsy, MRI Targeted Biopsy
Sunnybrook Health Sciences Centre, Exact Imaging
Prostate Cancer
09/24
11/24
CISTO, NCT03933826: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

Active, not recruiting
N/A
572
US
University of Washington, Patient-Centered Outcomes Research Institute
Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
01/25
06/29
NCT03988309: STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

Active, not recruiting
N/A
554
Canada, US
Cxbladder
Pacific Edge Limited
Hematuria, Urothelial Carcinoma
12/24
12/24
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Tewari, Ashutosh K
NCT06945315: SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)

Recruiting
3
196
US
RALP (Robotic-assisted radical prostatectomy), SAFE (Saline assisted fascial engorgement)
Icahn School of Medicine at Mount Sinai
Prostate Cancer, Erectile Dysfunction
07/27
07/27
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
NCT06343077: Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance

Recruiting
2
114
US
Poly-ICLC intramuscular (IM) injection, Hiltonol®, Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose, Poly-ICLC, Intertumoral (IT) injection
Ashutosh Kumar Tewari, Oncovir, Inc.
Prostate Cancer Patients on Active Surveillance
12/26
12/26
LORIKEET, NCT05848011: A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting
2
154
Europe, US, RoW
lorigerlimab, MGD019, docetaxel, Taxotere®, Prednisone
MacroGenics
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
09/26
09/27
NCT06906471: A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Not yet recruiting
1/2
10
US
AS1986NS
Antelope Surgical Solutions, Inc
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Fluorescence Imaging
12/25
03/26
PGV-Prostate, NCT05010200: The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

Active, not recruiting
1
27
US
PGV-001, Poly-ICLC, CDX-301
Ashutosh Kumar Tewari
Prostate Cancer
01/27
01/28
NCT04761107: Impact of COVID-19 on GU Disease

Active, not recruiting
N/A
15240
US
Icahn School of Medicine at Mount Sinai
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
02/26
02/26
Osterhout, Danielle
PIVOT-006, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT06533644: A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
70
US
Partial Oncolysis, cryolysis, SV-102
Syncromune, Inc.
Metastatic Castration-resistant Prostate Cancer
12/27
12/27
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Wilner, Matthew
ORIC-944-01, NCT05413421: Study of ORIC-944 in Patients with Metastatic Prostate Cancer

Recruiting
1
250
Europe, US, RoW
ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets, Darolutamide (Nubeqa®) 300 mg tablets, Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
ORIC Pharmaceuticals
Metastatic Prostate Cancer
12/25
09/26
Barnette
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
ARTEST, NCT04869943 / 2021-002176-39: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Terminated
3
52
Europe, US, RoW
Enobosarm, VERU-024, Exemestane, Mestane
Veru Inc.
Metastatic Breast Cancer
01/24
01/24
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

Active, not recruiting
2
150
US
Enobosarm, Semaglutide, Wegovy
Veru Inc.
Muscle Loss, Obesity
12/24
04/25
NCT03752099: To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Terminated
1b/2
80
US
VERU-111, Bisindole
Veru Inc.
Metastatic Castration Resistant Prostate Cancer
03/23
03/23
Thoreson, Gregory
SEPTA, NCT04583072: Stockholm3 Validation Study in a Multi-Ethnic Cohort

Completed
N/A
2152
Canada, US
The Stockholm3 test, Diagnostic Test: Custom ancestry informative genetic markers
Karolinska Institutet, University of Illinois at Chicago, UroPartners, University of Chicago, Rush University Medical Center, Montefiore Medical Center, The University of Texas Health Science Center at San Antonio, Cook County Health & Hospitals System, Cook County Health, Stanford University, Northwestern Medicine, University of Southern California, University Health Network, Toronto, Urology Clinics of North Texas, LAC+USC Medical Center
Prostate Cancer (Diagnosis)
07/23
07/23
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29
Grewal, Shaun GS
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
Mehllhaff, Bryan
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
12/25
12/25
Park, Gerald
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37
Valverde, Christian
WATER IV PCa, NCT06651632: WATER IV Prostate Cancer

Recruiting
N/A
280
Europe, Canada, US, RoW
Aquablation Therapy, Radical Prostatectomy
PROCEPT BioRobotics
Localized Prostate Cancer
07/27
01/37

Download Options